4DMT Partnership drives gene therapy expansion in Asia-Pacific
On October 31, 2025, California-based 4D Molecular Therapeutics (4DMT) announced a strategic partnership with Japan’s Otsuka Pharmaceutical Co., Ltd. The agreement grants Otsuka exclusive rights to develop and commercialize 4DMT’s investigational gene therapy candidate, 4D-150, across the Asia-Pacific region. The 4DMT Partnership marks a major milestone in cross-border biotechnology collaborations focused on ophthalmic diseases.
The therapy, 4D-150, is designed to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the most common causes of adult vision loss. With this deal, Otsuka gains access to 4DMT’s proprietary vector platform and manufacturing technology, enabling rapid clinical development across markets such as Japan, South Korea, Australia, and Singapore.
Strategic objectives of the 4DMT Partnership
Under the terms of the deal, Otsuka will pay 4DMT an upfront payment of $150 million, with potential milestone payments reaching up to $800 million, along with royalties on future sales. This 4DMT Partnership underscores the growing interest of large pharmaceutical companies in gene therapy platforms capable of addressing ophthalmic and rare genetic disorders.
According to 4DMT CEO David Kirn, the partnership builds on both companies’ commitment to deliver durable, one-time treatments for chronic eye diseases. Otsuka’s extensive regional network and regulatory experience are expected to accelerate clinical trial approvals and distribution logistics, positioning 4D-150 as a leading candidate in the ophthalmic gene therapy market.
Impact on global gene therapy development
This collaboration arrives amid a global surge in investment toward gene and cell therapy solutions, with Asia-Pacific emerging as a key growth market. The 4DMT Partnership strategically aligns with Otsuka’s long-term goal of expanding its advanced therapeutics portfolio, following earlier investments in neuroscience and digital medicine. For 4DMT, the deal secures significant non-dilutive capital and enhances its reach beyond North America and Europe.
Analysts suggest that this partnership could reshape competitive dynamics in the ophthalmic treatment sector. By leveraging 4DMT’s AAV-based vector innovation, Otsuka could fast-track next-generation therapies that deliver sustained efficacy and reduced injection frequency compared to conventional anti-VEGF drugs.
Future outlook and leadership vision
Both companies have indicated plans to initiate Phase 3 clinical trials for 4D-150 in early 2026. The success of this program may extend beyond ophthalmology, opening doors to gene therapy applications in other chronic conditions. The 4DMT Partnership demonstrates the increasing importance of regional alliances in accelerating regulatory access and optimizing patient outcomes in precision medicine.
As regulatory agencies across Asia strengthen their frameworks for advanced therapies, partnerships like this are poised to define the next era of cross-border biotechnology innovation. With Otsuka’s established presence in Japan and 4DMT’s pioneering R&D capabilities, the collaboration represents a model for sustainable innovation and equitable access to breakthrough treatments.
